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comes were quantified using a correlational matrix to de-
termine relationship between different endpoints. 
RESULTS: Three OXY-XL randomized clinical trials and
one open label safety trial and three TOL trials were iden-
tified. All reported rate of reduction of urinary inconti-
nence episodes (R-UI). The OXY-XL trials reported rate of
complete continence (CC), defined as percent of patients
with no UI episodes for 7 days. Mean CC rates for OXY-
XL ranged from 41% to 50% (mean CC rate  45.9% 
0.04). OXY-XL mean R-UI ranged from 79.5% to 89.5%
(mean R-UI  84.4%  0.04). For TOL, R-UI rates
ranged from 43.2% to 44.8%, (mean R-UI  45.7% 
0.02). Computed CC rate for TOL was 24.6%. Correla-
tion across all studies between CC and R-UI was high
(r2  0.9975, p  0.0001) and consistent; R-UI:CC ratios
within trials ranged from 1.8 to 1.9 (mean  1.85 
0.08). Rate of reduction in UI episodes/week or day is ap-
proximately twice that of complete continence. 
CONCLUSIONS: Rate of complete continence may be
derived from a surrogate endpoint by taking approxi-
mately one half the rate of reduction in R-UI episodes
weekly, allowing direct efficacy comparisons on multiple
measures.
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Overactive bladder affects 17 million Americans who
present with symptoms of urge urinary incontinence
(UUI), urgency or urinary frequency. Providers and payers
may select the most appropriate treatment using outcomes
recommended by the International Continence Society
(ICS): symptom quantification, patient’s observations of
symptoms and HRQoL. 
OBJECTIVE: Using ICS-recommended outcome mea-
sures, efficacy of a newly approved once daily, controlled
release formulation of oxybutynin (OXY-XL) was evalu-
ated in an open-label 16-center trial.
METHOD: In this study 256 patients with urge/mixed
urinary incontinence were treated with OXY-XL 5–30mg
up to 18 weeks. Outcomes were assessed at baseline and
maintenance dose week 12. Symptom quantification was
based on 7-day diaries of voiding and incontinence
events. Symptom bother was collected with the Urge-
Urogenital Distress Inventory (U-UDI); HRQoL was col-
lected with the disease-specific Urge-Incontinence Impact
Questionnaire (U-IIQ). 
RESULTS: Outcome was based on 206 patients with
baseline and 12-week data. OXY-XL led to significant
reductions in UUI episodes at 12 weeks versus baseline
(83%, p  0.001). Percent of patients with complete
continence increased from 5% to 46%, p  0.001. At
study end, patients perceived significantly less bother on
all nine symptoms (i.e., urine leakage, frequency, urgency,
nighttime urination) measured by the U-UDI (mean
change  49%, range 30 to 62%, p  0.001).
HRQoL was significantly improved as measured by the
U-IIQ overall score (59%, p  0.001) as well as all
eight domains (range 59% to 61%, p  0.001). 
CONCLUSION: Patients treated with OXY-XL had sta-
tistically significant improvements in all outcomes: UUI
episodes, complete continence, HRQoL and symptom
bother.
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The increasing number of quality of life (QoL) assess-
ments in multinational clinical trials emphasizes the need
for cross-culturally valid instruments to pool data across
countries. The Urinary Incontinence QoL Questionnaire
is a 28-item questionnaire developed in French and de-
signed for use in women with urinary incontinence and
investigates five domains and overall QoL. Prior to use in
an international trial, the original questionnaire under-
went linguistic validation in six countries. 
METHODS: The rigorous methodology involved recruit-
ing a QoL specialist in each country to supervise the lin-
guistic validation process. For practical reasons, a UK
English version was produced prior to the other transla-
tions as a translation basis along side the French original.
The following methodology was employed: two forward
translations by two native target language speakers;
back-translation into French; comprehension test in a
sample target population and international harmoniza-
tion. The remaining languages followed the same process
basing themselves both on the French and UK texts dur-
ing forward and backward translations. 
RESULTS: Linguistic issues emerged, among which the
translation of idiomatic French expressions such as “feel-
ing well in one’s skin” or “discouraged” for which de-
scriptive equivalents had to be found in most languages
to retain the original concept. Conceptual issues arose
where the French original could be interpreted in more
than one way. Close collaboration with the author was
necessary to correctly interpret the original concepts and
orient translations towards the correct interpretation. 
CONCLUSION: A rigorous methodology ensured con-
ceptual equivalence and acceptability of the translations.
Psychometric testing will be conducted to ensure reliabil-
ity and validity of each translation, appropriateness of
